Last Updated : April 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Keytruda | Pembrolizumab | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Lynparza | Olaparib | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Adcetris | brentuximab vedotin | Hodgkin lymphoma | Withdrawn | |||
| Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Pending | |||
| TBC | leniolisib | Activated phosphoinositide 3 kinase delta syndrome | Pending | |||
| Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
| TBC | avapritinib | Advanced Systemic Mastocytosis | Pending | |||
| TBC | exagamglogene autotemcel | Transfusion-dependent β-thalassemia | Pending | |||
| TBC | exagamglogene autotemcel | Sickle cell disease (SCD) | Pending | |||
| TBC | rozanolixizumab | Generalized myasthenia gravis (gMG). | Pending |
Last Updated : April 19, 2024